炎症性肠病患者监测性结肠镜检查间隔对结直肠癌结局的比较有效性:全国队列研究
该回顾性队列研究纳入美国退伍军人健康管理局2000至2015年77,824例炎症性肠病患者中确诊结直肠癌的566例,分析结肠镜监测间隔与肿瘤分期及死亡率的关系。结果显示,与未监测相比,诊断前1年内和1至3年内行结肠镜者晚期诊断风险更低,1年内行结肠镜与较低全因死亡率相关。
要点
- 诊断前1年内行结肠镜与较低晚期诊断风险相关(调整OR 0.40,95%CI 0.20-0.82)。
- 诊断前1至3年内行结肠镜与较低晚期诊断风险相关(调整OR 0.56,95%CI 0.32-0.98)。
- 诊断前1年内行结肠镜与较低全因死亡率相关(调整HR 0.56,95%CI 0.36-0.88)。
核心结论
- 在炎症性肠病相关结直肠癌患者中,诊断前3年内行结肠镜与诊断时肿瘤分期较早相关,诊断前1年内行结肠镜与全因死亡率降低相关(对比未行结肠镜)。
- 作者认为研究结果支持对炎症性肠病患者采用1至3年的结肠镜监测间隔,以降低晚期结直肠癌和全因死亡率。
研究设计与样本
- 回顾性队列研究,基于美国退伍军人健康管理局2000至2015年77,824例炎症性肠病患者队列,纳入其中确诊结直肠癌的566例患者。
- 按结直肠癌诊断前结肠镜间隔分为<1年、1至3年、3至5年和5年内无结肠镜四组。
主要发现
- 566例炎症性肠病相关结直肠癌患者中,69.4%在诊断前5年内未行结肠镜,9.7%在诊断前1年内行结肠镜,17.7%在1至3年内,3.1%在3至5年内。
- 与未监测相比,诊断前1年内行结肠镜者晚期诊断风险更低(调整OR 0.40,95%CI 0.20-0.82),1至3年内行结肠镜者晚期诊断风险亦更低(调整OR 0.56,95%CI 0.32-0.98)。
- 无论炎症性肠病类型和病程如何,诊断前1年内行结肠镜与较低全因死亡率相关(调整HR 0.56,95%CI 0.36-0.88)。
关键数值与推荐
- 原文未报告结肠镜监测间隔的具体推荐等级或强度标签。
临床怎么用
- 作者认为研究结果支持对炎症性肠病患者采用1至3年的结肠镜监测间隔,以降低晚期结直肠癌和全因死亡率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Surveillance colonoscopy is recommended to reduce colorectal cancer (CRC)-related morbidity and mortality in patients with inflammatory bowel disease (IBD). The comparative effectiveness of varying colonoscopy intervals on CRC outcomes among patients with IBD is unknown. METHODS: We performed a retrospective cohort study of patients with confirmed CRC within a cohort of 77,824 patients with IBD during 2000 to 2015 in the National Veterans Health Administration. We examined the association between colonoscopy surveillance intervals on CRC stage, treatment, or all-cause and cancer-specific mortality. The interval of colonoscopy prior to CRC diagnosis was categorized as those performed within <1 year, 1 to 3 years, 3 to 5 years, or none within 5 years. RESULTS: Among 566 patients with CRC-IBD, most (69.4%) did not have colonoscopy within 5 years prior to CRC diagnosis, whereas 9.7% had colonoscopy within 1 year prior to diagnosis, 17.7% within 1 to 3 years, and 3.1% between 3 and 5 years. Compared with no surveillance, colonoscopy within 1 year (adjusted odds ratio, 0.40; 95% confidence interval [CI], 0.20-0.82), and 1 to 3 years (adjusted odds ratio, 0.56; 95% CI, 0.32-0.98) were less likely to be diagnosed at late stage. Regardless of IBD type and duration, colonoscopy within 1 year was associated with a lower all-cause mortality (adjusted hazard ratio, 0.56; 95% CI, 0.36-0.88). CONCLUSIONS: In a national cohort of patients with CRC-IBD, colonoscopy within 3 years prior to CRC diagnosis was associated with early tumor stage at diagnosis, and colonoscopy within 1 year was associated with a reduced all-cause mortality compared with no colonoscopy. Our findings support colonoscopy intervals of 1 to 3 years in patients with IBD to reduce late-stage CRC and all-cause mortality.
引用
- Kim HS, Hernaez R, Sansgiry S, et al. Comparative Effectiveness of Surveillance Colonoscopy Intervals on Colorectal Cancer Outcomes in a National Cohort of Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2022. PMID: 35240331. doi:10.1016/j.cgh.2022.02.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。